ArticleParasite (Paris, France)2025
Evaluating the pathogenic and immunological effects of ds-GFP as a control in in vivo RNA interference studies of Schistosoma japonicum.
Article in Parasite (Paris, France), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Schistosomiasis affects over 250 million people in 78 countries. Despite praziquantel as the primary treatment, concerns about resistance in schistosomes underscore the need for alternative therapies. The success of RNA interference (RNAi) in schistosomes shows promise for identifying potential drug targets to facilitate drug discovery. Meanwhile, double-stranded RNA (dsRNA) is commonly used in functional gene analysis via RNAi, with double-stranded green fluorescent protein (ds-GFP) widely employed as a control in schistosome-related studies. However, the potential for off-target effects of dsRNAs in various biological systems raises concerns about the reliability of conventional controls in schistosome RNAi experiments. Therefore, this study aims to evaluate the safety and suitability of ds-GFP as an RNAi negative control in Schistosoma japonicum. Our data indicate that ds-GFP is innocuous and exerts no discernible impact on the host's physiology and immune responses. Comprehensive evaluations conducted in mice showed no significant alterations in body and organ weights. While a splenic immune response was observed, histopathological examinations of multiple organs confirmed the absence of significant lesions following ds-GFP treatment. Additionally, S. japonicum morphology, reproductive capacity, and host responses to parasite eggs showed no significant variations. Taken together, these findings bolster the endorsement of ds-GFP as an appropriate negative control in S. japonicum RNAi experiments, offering reliable outcomes crucial for advancing research on schistosomiasis and related parasitic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.